Quest $DGX delivers another beat and raise, been quietly a very strong story the past year Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance Advanced Diagnostics categories — including Alzheimer's blood tests and cardiometabolic/endocrine panels — showed double-digit growth, and the company continued to deploy automation and digital tools that support margin sustainability. The share repurchase program remains active, with $1.3 billion still available under the current authorization following $100 million in buybacks during Q2.
View on X ↗